 A phase III clinical trial of a lung cancer drug developed by AstraZeneca PLC LSE:AZN and Daiichi Sankyo is expected to show positive results, according to a leading investment bank. The treatment, called Dato-DXd, is being tested in patients with non-small cell lung cancer NSCLC and is aimed at improving progression-free survival PFS. 